主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VSTM
#2622
Verastem, Inc.
5.7
2
+1.42%
版块:
基础:
利润货币:
日范围
年范围
日变化
+1.42%
每月变动
-11.86%
6个月变化
-38.49%
年变化
+6.32%
前一天收盘价
5.6
4
Open
5.7
2
Bid
Ask
Low
5.7
2
High
5.7
2
交易量
58
市场
股票
医疗保健
VSTM
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Total assets
126.38 M
101.54 M
131.7 M
196.26 M
176.85 M
Total liabilities
94.16 M
130.43 M
164.13 M
160.21 M
192.38 M
Total equity
11.06 M
28.89 M
32.43 M
36.06 M
15.53 M
Total liabilities & shareholders' equities
126.38 M
101.54 M
131.7 M
196.26 M
176.85 M
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
Verastem Inc
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
新闻
What Makes Verastem (VSTM) a New Buy Stock
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
B.Riley重申Verastem股票买入评级,维持16美元目标价
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target
Verastem报告癌症治疗第四季度收入达1750万美元
Verastem reports $17.5 million in Q4 revenue for cancer treatment
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)
Revolution Medicines stock surges over 20% on potential AbbVie acquisition
艾伯维或收购Revolution Medicines,后者股价飙升超20%
What's Going On With Verastem Stock Friday? - Verastem (NASDAQ:VSTM)
Verastem股票稳定 Mizuho重申"优于大盘"评级